Cargando…

Coagulatory Defects in Type-1 and Type-2 Diabetes

Diabetes (both type-1 and type-2) affects millions of individuals worldwide. A major cause of death for individuals with diabetes is cardiovascular diseases, in part since both types of diabetes lead to physiological changes that affect haemostasis. Those changes include altered concentrations of co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sobczak, Amélie I. S., Stewart, Alan J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6940903/ https://www.ncbi.nlm.nih.gov/pubmed/31888259 http://dx.doi.org/10.3390/ijms20246345

Ejemplares similares

Changes in Plasma Free Fatty Acids Associated with Type-2 Diabetes
por: I. S. Sobczak, Amélie, et al.
Publicado: (2019)

Coagulatory active constituents of Malus pumila Mill. flowers
por: Yin, Zhenhua, et al.
Publicado: (2018)

Response patterns of routinely measured inflammatory and coagulatory parameters in sepsis
por: Bachler, Mirjam, et al.
Publicado: (2019)

Inflammatory and coagulatory parameters linked to survival in critically ill children with sepsis
por: Niederwanger, Christian, et al.
Publicado: (2018)

Total plasma magnesium, zinc, copper and selenium concentrations in type-I and type-II diabetes
por: Sobczak, Amélie I. S., et al.
Publicado: (2019)

Anti-inflammatory and anti-coagulatory activities of caffeic acid and ellagic acid in cardiac tissue of diabetic mice
por: Chao, Pei-chun, et al.
Publicado: (2009)

Low-molecular-weight heparin-coated cardiopulmonary bypass: coagulatory and clinical findings
por: Mirow, N, et al.
Publicado: (2001)

Reduced Plasma Magnesium Levels in Type-1 Diabetes Associate with Prothrombotic Changes in Fibrin Clotting and Fibrinolysis
por: Sobczak, Amélie I. S., et al.
Publicado: (2020)

Lipidomic profiling of plasma free fatty acids in type-1 diabetes highlights specific changes in lipid metabolism
por: Sobczak, Amélie I.S., et al.
Publicado: (2021)

Bladder cancer-derived interleukin-1 converts the vascular endothelium into a pro-inflammatory and pro-coagulatory surface
por: John, A., et al.
Publicado: (2020)

Oral contraceptive use increases risk of inflammatory and coagulatory disorders in women with Polycystic Ovarian Syndrome: An observational study
por: Manzoor, Saika, et al.
Publicado: (2019)

Isolation, purification, structural analysis and coagulatory activity of water-soluble polysaccharides from Ligustrum lucidum Ait flowers
por: Yin, Zhenhua, et al.
Publicado: (2017)

Glycosaminoglycan Neutralization in Coagulation Control
por: Sobczak, Amélie I.S., et al.
Publicado: (2018)

Albumin-mediated alteration of plasma zinc speciation by fatty acids modulates blood clotting in type-2 diabetes
por: Sobczak, Amélie I. S., et al.
Publicado: (2021)

Metabolomics of Type 1 and Type 2 Diabetes
por: Arneth, Borros, et al.
Publicado: (2019)

Inflammatory and coagulatory markers and exposure to different size fractions of particle mass, number and surface area air concentrations in Swedish iron foundries, in particular respirable quartz
por: Westberg, Håkan, et al.
Publicado: (2019)

The Role of MIF in Type 1 and Type 2 Diabetes Mellitus
por: Sánchez-Zamora, Yuriko I., et al.
Publicado: (2014)

Influence of zinc on glycosaminoglycan neutralisation during coagulation
por: Sobczak, Amélie I. S., et al.
Publicado: (2018)

Better Gingival Status in Patients with Comorbidity of Type 1 Diabetes and Thyroiditis in Comparison with Patients with Type 1 Diabetes and No Thyroid Disease—A Preliminary Study
por: Duda-Sobczak, Anna, et al.
Publicado: (2023)

Cardiovascular outcomes in type 1 and type 2 diabetes
por: Rosengren, Annika, et al.
Publicado: (2023)

Management of Type 2 Diabetes in Older People
por: Abdelhafiz, Ahmed H., et al.
Publicado: (2013)

Insulin Detemir in the Treatment of Type 1 and Type 2 Diabetes
por: Philips, Jean-Christophe, et al.
Publicado: (2006)

Insulin Glargine in the Treatment of Type 1 and Type 2 Diabetes
por: Barnett, Anthony H
Publicado: (2006)

Treg activation defect in type 1 diabetes: correction with TNFR2 agonism
por: Okubo, Yoshiaki, et al.
Publicado: (2016)

Low-Carb and Ketogenic Diets in Type 1 and Type 2 Diabetes
por: Bolla, Andrea Mario, et al.
Publicado: (2019)

Role of Innate Immunity in the Pathogenesis of Type 1 and Type 2 Diabetes
por: Lee, Myung-Shik
Publicado: (2014)

Mast Cells and the Pancreas in Human Type 1 and Type 2 Diabetes
por: Masini, Matilde, et al.
Publicado: (2021)

Immune cell infiltration in the pancreas of type 1, type 2 and type 3c diabetes
por: Kattner, Nicole
Publicado: (2023)

Therapeutic Potential of Alpha-1 Antitrypsin in Type 1 and Type 2 Diabetes Mellitus
por: Park, Sangmi S., et al.
Publicado: (2021)

Alternatively Activated Macrophages in Types 1 and 2 Diabetes
por: Espinoza-Jiménez, Arlett, et al.
Publicado: (2012)

Galectin-1 in Obesity and Type 2 Diabetes
por: Fryk, Emanuel, et al.
Publicado: (2022)

Pramlintide in the Management of Insulin-Using Patients with Type 2 and Type 1 Diabetes
por: Pullman, John, et al.
Publicado: (2006)

Review of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetes
por: Ryan, Gina, et al.
Publicado: (2009)

Systematic Review of Polygenic Risk Scores for Type 1 and Type 2 Diabetes
por: Padilla-Martínez, Felipe, et al.
Publicado: (2020)

2022: Position of Brazilian Diabetes Society on exercise recommendations for people with type 1 and type 2 diabetes
por: Pereira, William Valadares Campos, et al.
Publicado: (2023)

The Interplay between Non-Esterified Fatty Acids and Plasma Zinc and Its Influence on Thrombotic Risk in Obesity and Type 2 Diabetes
por: Hierons, Stephen J., et al.
Publicado: (2021)

Skeletal Muscle Insulin Resistance Is the Primary Defect in Type 2 Diabetes
por: DeFronzo, Ralph A., et al.
Publicado: (2009)

Personality types in individuals with type 1 and type 2 diabetes
por: Rouland, A, et al.
Publicado: (2020)

Analog insulin detemir for patients with type 1 and type 2 diabetes: a review
por: Peterson, Gregory E
Publicado: (2009)

Insulin degludec/insulin aspart combination for the treatment of type 1 and type 2 diabetes
por: Dardano, Angela, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_rrd7lor3knq1amml7f3a5imb32